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Central Message
Current transatrial-transpulmonary ToF correc-
tion shows excellent survival, though residual
PS or PR remain an area of concern often lead-
ing to RA and RV dilation or reintervention.
Perspective Statement
Only few studies reported outcome of the trans-
atrial-transpulmonary approach, often with fol-
low-up durations <5 years. We investigated
long-term outcome of total transatrial-transpul-
monary ToF correction in 177 patients operated
since 2000. Differences between surgical
approaches for reconstruction of the right ven-
tricular outflow tract were assessed and risk fac-
tors for adverse outcome were analyzed.Only few studies have reported long-term outcome of the transatrial-transpul-
monary approach in the current era of management of tetralogy of Fallot (ToF).
We investigated 15-year outcome of correction via a transatrial-transpulmonary
approach in a large cohort of successive patients operated in the 21st century.
All infant ToF patients undergoing transatrial-transpulmonary ToF correction
between 2000 and 2015 were included (N= 177, 106 male, median follow-up
7.1 (interquartile range 3.010.9) years. Data regarding postoperative complica-
tions, reinterventions, development of atrial and ventricular arrhythmia, cardiac
function, and survival were evaluated. Prior shunting was performed in 10
patients (6%). The transatrial-transpulmonary approach resulted in valve-spar-
ing surgery in 57 patients (32%). Postoperative surgical complications included
junctional ectopic tachycardia (N= 12, 7%), pericardial (N = 10, 6%) or pleural
effusion (N= 7, 3%), chylothorax (N= 7, 4%), bleeding requiring reoperation
(N = 4, 3%), and superﬁcial wound infection (N= 1). Fifty-one patients under-
went 68 reinterventions, mainly due to pulmonary restenosis (PS) (N = 57). ToF
correction at age <2 months and double outlet or double-chambered right ven-
tricle variants of the ToF spectrum were independent predictors for reinterven-
tion. Patients undergoing valve-sparing ToF correction had a signiﬁcant longer
PR-free survival than those with D20X Xa transannular patch (8.5 [95% conﬁdence
interval 6.810.3] years vs 1.1 [95% conﬁdence interval 0.81.5] years; P <
0.001). Overall mortality was 2.8%; mortality rates were higher in premature/
dysmature newborns (0.7% vs 9.5%; P < 0.001). Although the 15-year outcome
of the transatrial-transpulmonary approach in terms of postoperative complica-
tions and mortality rates is excellent, the high incidence of moderate and severe
PR is worrisome. Valve-sparing surgery was associated with a substantially
lower incidence of PR, yet was surgically not possible in the majority of patients.
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CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERAINTRODUCTION detailed intraoperative inspection of the pulmonary valve per-
Over the past decades, surgical treatment for various con-
genital heart diseases has improved tremendously. Speciﬁcally,
the introduction of the transatrial-transpulmonary approach
for total tetralogy of Fallot (ToF) correction by Hudspeth et al
in the early 60s lead to high expectations for long-term survival
of ToF patients.1 Previous studies in populations primarily
operated between 1970 and 1990 identiﬁed several risk factors
for late adverse outcome such as reoperation, arrhythmia
development or death, including prior palliative shunting,
early postoperative arrhythmias, use of a transannular patch
(TAP), lower body temperature during surgery, and tricuspid
insufﬁciency.26
Thus far, only a few studies reported on intermediate or late
outcome of the transatrial-transpulmonary approach in the
current era of surgical management, which often had follow-
up durations less than 5 years.4,79 Furthermore, the inﬂuence
of additional comorbidities or syndromic diseases is rarely
taken into account, hampering decision-making processes for
these patients.
In this study, we investigated 15-year outcome of total ToF
correction via a transatrial-transpulmonary approach in a large
cohort of successive patients operated between 2000 and
2015. Differences between patients with and without comor-
bidities and between surgical approaches for reconstruction of
the right ventricular outﬂow tract (RVOT) were assessed. In
addition, risk factors for adverse outcome were analyzed.
METHODS
Study Population
Data of all infant ToF patients who underwent total surgical
correction at our center from 2000 till 2015 were retrospec-
tively retrieved. ToF patients with pulmonary atresia (ToF-PA)
or with a complete atrioventricular septal defect (ToF-CAVSD)
were excluded from our dataset, as these are considered a sepa-
rate entity with a different surgical approach. ToF patients with
a double-chambered right ventricle (DCRV) variant, that is,
more extensive crossing muscle bundles at the RVOT resulting
in the DCRV, and with a double outlet right ventricle (DORV)
variant, that is, >50% overriding of the aorta, were included.
This study is part of the DANARA-project, which primary aim
is to examine the development of various dysrhythmias in
CHD patients (MEC 2012-482); informed consent was not
required.
Total ToF Correction
Transatrial-transpulmonary repair of ToF included closure
of the ventricular septal defect (VSD) through the tricuspid
valve with a Gore-Tex patch, while RVOT enlargement was
performed by myotomy/myectomy through the tricuspid valve
or, if necessary, through the pulmonary valve (PV). RVOT
enlargement with TAP is considered in patients with a preoper-
atively echocardiographically assessed PV annulus z-score ≤2,
indicated by the Boston z-score system, combined with a2 Seminars in Thformed via an incision in the pulmonary truncus. In case the
pulmonary valve is dysplastic or the annulus a vue is indeed
too narrow as indicated by Hegar measurement, the incision in
the pulmonary truncus was extended till the transitional bor-
der of the infundibulum at the discretion of the attending sur-
geon. A glutaraldehyde-pretreated pericardial patch was used
for the TAP. Obstructive valve tissue was removed, whereas
functional valve tissue was left in situ. In case of a pulmonary
annulus of sufﬁcient size and morphologically functional val-
vular leaﬂets, a valve-sparing approach is pursued, in which
commissurotomy or Hegar dilation is performed if necessary,
in addition to desobstruction of the infundibulum. Surgical
success of RVOT desobstruction was assessed intraoperatively
by echocardiographic Doppler ﬂow <2 m/s and at maximum
half systemic pressures in the RV.
Data Collection
Data regarding gestational age at birth were collected from
digital patient ﬁles and premature/dysmature patients were dis-
tinguished from full-term newborns. Prematurity was deﬁned
as gestational age <37 weeks; dysmaturity was deﬁned as ≤2
SD from the mean intrauterine growth curve.
Surgical and anesthetic reports were reviewed for documen-
tation of (additional) cardiac anomalies, presence of palliative
aortopulmonary shunts, description of surgical techniques
used for total ToF correction, total cardiopulmonary bypass
time, aortic crossclamp time, and height and weight of the
patient prior to surgery.
Surgical complications occurring within 30 days after sur-
gery were collected, including pleural effusion needing drain-
age, pericardial effusion needing drainage or drug therapy,
chylothorax, severe renal insufﬁciency requiring hemodialysis,
bleeding requiring reoperation and thromboembolic events,
and prolonged intubation >2 days.
Early and late postoperative mortality was determined,
deﬁned as death ≤30 days and >30 days after total ToF correc-
tion, respectively.
Clinical data obtained at yearly outpatient follow-up visits
were collected from electronic patient ﬁles. An ECG was made
at each follow-up visit, and echocardiographic examination
was done at least once every 2 years in stable patients and
more frequently if indicated. Cardiac-MRI, 24-hour Holter
recordings and exercise tests were performed on clinical indi-
cation. All echocardiographic results during follow-up were
examined and the moment of ﬁrst presentation with greater
than moderate PR, PS, RV dilation and RA dilation was col-
lected. At the latest follow-up moment, echocardiographic
results of PR, PS, RV, and RA dilation and right ventricular
function (RVF) and left ventricular function (LVF) were col-
lected as well.
Medical correspondence, ECG, and Holter-recordings were
reviewed for documentation of tachyarrhythmias including
postoperative junctional ectopic tachycardia (JET), atrial ﬁbril-
lation (AF), other supraventricular tachycardia (SVT),oracic and Cardiovascular Surgery  Volume 00, Number 00
Table 1. Patient Characteristics
ToF patients 177
ToF-DORV variant 15 (8)
ToF-DCRV variant 15 (8)
Male 106 (60)
Age at ToF correction (months) 3.5 (IQR: 2.65.2;
min-max: 0.249.5)
Weight at ToF correction (kg) 5.8 § 2.2 (215.7)
Premature/dysmature 42 (24)
Associated cardiac anomalies 163 (92)
Atrial septal defect 151 (85)
Patent ductus arteriosus 45 (25)
Aberrant coronary artery 5 (3)
Persistent left superior caval vein 5 (3)
Branch pulmonary artery coarctation 2 (1)
Systemic-to-pulmonary collaterals 0 (0)
Additional syndromic disease 25 (14)
Trisomy 21 8 (4)
22q11-deletion 11 (6)
VACTERL 1 (0.7)
Rubinsteijn-Taybi 1 (0.7)
Opitz 1 (0.7)
Mowat-Wilson 1 (0.7)
Turner 1 (0.7)
Cornelia de Lange 1 (0.7)
Nonsyndromic extracardiac
abnormalities
21 (12)
Gastrointestinal 5 (3)
Cerebral 9 (5)
Urogenital 8 (4)
Surgical approach
Transatrial-transpulmonary correction 177
Prior palliative shunt 10 (6)
Valve-sparing surgery 5D1X X7 (3 D2X X )
DCRV, double-chambered right ventricle; DORV, double outlet right
ventricle; VACTERL, association of various malformation including Ver-
tebral defects, Anorectal malformation, Cardiac defects, Tracheo-
Esophageal ﬁstula, Renal anomalies, and Limb anomalies.
CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERAventricular tachycardia (VT), and ventricular ﬁbrillation (VF);
JET, AF, SVT, VT, and VF were deﬁned according to the pres-
ent guidelines.10
Statistical Analysis
Normally distributed data are described as mean § SD (min-
imum-maximum) and analyzed with a Student's t test or a one-
way ANOVA. Skewed data are described by median (interquar-
tile range) and analyzed with Kruskal-Wallis test or a Mann-
Whitney U test. Categorical data are expressed as numbers and
percentages and analyzed with x2 or Fisher exact test when
appropriate. Analysis of freedom from reintervention, freedom
from PS, PR, RA, and RV dilation and overall survival was per-
formed with the Kaplan-Meier Method. Univariate and multi-
variate predictors of reintervention and mortality were assessed
with a Cox regression analysis, in which 10 events per
included factor were required. Inﬂuence of mild, moderate,
and severe PS within 1 year after total ToF correction was
determined, using “no PS” as reference category.
RESULTS
Study Population
After exclusion of 25 patients with ToF-PA (N = 12, 6%) and
ToF-CAVSD (N = 13, 6%), a total of 177 ToF children who
underwent total ToF correction at our center were included.
Table 1 displays characteristics of the included 177 ToF
patients (median age last follow-up 8.3 [interquartile range
(IQR) 4.411.6; min-max 0.317.0] years, 106 male [60%]), of
whom 15 (8%) were diagnosed with a ToF-DORV variant and
another 15 (8%) with a ToF-DCRV variant. Median follow-up
time from total ToF correction was 7.8 (IQR 3.910.9; min-max
0.0316.9) years.
A total of 42 patients (24%) were dysmature or prematurely
born. Syndromic diseases occurred in 25 patients (14%) and
nonsyndromic extracardiac abnormalities were present in 21
patients (12%, Table 1). At last follow-up, the vast majority of
patients did not use any cardiovascular drugs or diuretics
(N = 173, 98%).
Total ToF Correction
Ten patients (6%) underwent prior palliative shunting
before undergoing total ToF correction at a later stage, includ-
ing 5 patients with severe cyanotic spells, 3 with a complex
RVOT, 1 who had an intercurrent infection leading to delay of
the total ToF correction, and 1 patient underwent prior pallia-
tive shunting abroad. Transatrial-transpulmonary total ToF
correction was performed at a median age of 3.5 months (IQR
2.65.2; min-max 0.249.5 months). Mean height and
weight at total ToF correction were 62 § 10 (40106) cm and
5.8 § 2.2 (215.7) kg, respectively. Valve-sparing surgery was
performed in 57 patients (32%). Median cardiopulmonary
bypass time was 111 minutes (IQR 76151; min-max
50398), and median aortic cross clamp time was 70 minutes
(IQR 48102; min-max 34167). Patients were extubatedSeminars in Thoracic and Cardiovascular Surgery  Volume 00within 2 days in the majority of cases (N = 150, 85%); 27
patients (15%) required prolonged intubation for a median of
5.5 days (IQR: 4¡10.5, min-max: 276).Early Surgical Outcome
Postoperative surgery-related complications are listed in
Table 2 and included pericardial (N = 10, 6%) or pleural effu-
sion (N = 7, 3%) requiring drainage, chylothorax (N = 7, 4%),
bleeding requiring reoperation (N = 4, 3%), and a superﬁcial
wound infection in 1 patient. Postoperative JET occurred in 12
patients (7%).
During hospital admission, acute renal failure requiring tem-
porary dialysis occurred in 1 patient and positive blood cul-
tures were observed in 10 patients (6%) for which antibiotic
treatment was started under the suspicion of venous catheter
septicemia; pneumonia did not occur in our cohort. Tempo-
rary pacemaker wires were placed preoperatively in 12 patients, Number 00 3
Table 2. Postoperative Complications
Postoperative complication 36 (20)
Pericardial effusion requiring drainage 10 (6)
Pleural effusion requiring drainage 7 (3)
Chylothorax 7 (4)
Bleeding requiring reoperation 4 (3)
Superﬁcial wound infection 1 (1)
Junctional ectopic tachycardia 12 (7)
CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERA(7%) due to atrioventricular conduction system disorders,
which recovered spontaneously before discharge in all cases.Echocardiographic Follow-Up
Figure 1 displays the echocardiographic follow-up of the
RVOT. Moderate or severe PS occurred in 78 patients (44%)
during follow-up. Mean freedom from D21X Xatleast moderate PS wasFigure 1. Freedom from pulmonary stenosis and pulmonary
regurgitation.
Kaplan-Meier plot describing freedom from pulmonary steno-
sis (upper panel) and freedom from pulmonary regurgitation
(lower panel). Conﬁdence intervals are displayed by interrupted
lines. Corresponding tables with the number of patients at risk
and the number of events for each time point are provided
below the plot.
4 Seminars in Th9.1 years (96% conﬁdence interval [CI] 7.810.4 years) and,
against expectation, was better in patients who underwent
valve-sparing ToF correction (11.6 years, 95% CI 9.713.5
years) compared to those receiving TAP (8.0 years, 95% CI
6.59.5 years; P = 0.008), as displayed in Figure 2.
As expected in a cohort mainly undergoing ToF correction
with TAP, the overall incidence of D22X Xatleast moderate PR was
76% (N = 135). Mean freedom from atleast D23X Xmoderate PR was
3.2 years (95% CI 2.54.0 years, Fig. 1). Patients undergoing
valve-sparing ToF correction had a signiﬁcant longer PR-free
survival than those with TAP (8.5 [95% CI 6.810.3] years vs
1.1 [95% CI 0.81.5] years; P < 0.001, Fig. 2).
A total of 106 patients (60%) showed D24X Xatleast moderate RV
dilation and 80 patients (45%) showed D25X Xatleast moderate RA
dilation at some point during follow-up. Mean freedom of
D26X Xatleast moderate RV and RA dilation was, respectively, 6.3
(95% CI 5.37.4) years and 8.7 (95% CI 7.69.9) years.
As a consequence of less PR, patients undergoing valve-spar-
ing correction also showed a far longer freedom from D27X Xatleast
moderate RA and RV dilation, as presented in Figure 2 (RA
dilation: 12.5 [95% CI 10.614.6] years vs 7.3 [95% CI
6.08.6] years [P < 0.001] and 11.7 [95% CI 9.713.7] years
vs 4.4 [95% CI 3.55.3] years [P < 0.001]).
At last follow-up, PS was present in 103 patients (58%),
including mild PS (N = 85, 48%), moderate PS (N = 14, 8%)
and severe PS (N = 4, 2%). PS was located subvalvular
(N = 27, 15%), valvular (32, 18%), supravalvular (N = 12,
7%), combined subvalvular and valvular (N = 17, 10%), val-
vular and supravalvular (N = 8, 5%) or at all 3 sites (N = 6,
3%). At D 28 X Xleast moderate PS occurred in 13% (N = 16) of TAP
patients vs 4% (N = 2) of valve-sparing patients at last follow-
up (P < 0.001).
A total of 144 patients (81%) showed PR at last follow-up,
which was mild in 26 patients (15%), moderate in 45 patients
(25%) and severe in 72 patients (41%). At least moderate PR
occurred in 85% (N = 112) of TAP patients vs 26% (N = 15) of
valve-sparing patients at last follow-up (P < 0.001).
Mild, moderate, and severe RA dilation occurred in, respec-
tively, 69 (39%), 40 (23%), and 4 patients (2%), whereas mild,
moderate, and severe RV dilation occurred in 66 (37%), 43
(24%), and 4 patients (2%) at last follow-up. Hence, severity of
PS, PR, RA, ad RV dilation ﬂuctuates during follow-up.
RVF and LVF remained well preserved in the majority of
patients; mild RV dysfunction occurred in 15 patients (9%),
who all had a normal LVF. Moderately and severely impaired
RVF and LVF occurred in, respectively, 2 and 1 patient.Late Surgical Outcome
During follow-up, reinterventions including redo surgery
and percutaneous procedures were required in 51 patients
(29%) (1 reintervention: N = 37 [73%]; 2 reinterventions:
N = 11 [22%]; 3 reinterventions: N = 3 [5%]). As displayed in
the upper panel of Figure 3, mean freedom from reintervention
was 11.2 (95% CI 10.012.3) years.oracic and Cardiovascular Surgery  Volume 00, Number 00
Figure 2. Differences between valve-sparing and nonvalve-sparing surgery.
Differences in the development of pulmonary stenosis (upper left panel), pulmonary regurgitation (upper right panel), right atrial
dilation (lower left panel), and right ventricular dilation (lower right panel) between patients undergoing valve-sparing surgery and
patients undergoing nonvalve-sparing surgery. Conﬁdence intervals are displayed by interrupted lines. Corresponding tables with
the number of patients at risk and the number of events for each time point are provided below the plot.
CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERAReinterventions (N = 68) mainly included reoperation for PS
(N = 36, 53%; in 35 patients) and percutaneous pulmonary
balloon dilation or stent placement for PS (N = 19, 28%; in 13
patients). In a minority of patients, reintervention consisted of
homograft placement due to PR (N = 7, 10%; in 7 patients),
residual VSD closure (N = 3, 4%; in 3 patients), or a combina-
tion of redo surgery for PS and residual VSD closure (N = 3,
4%; in 3 patients).
Median time interval from total ToF correction to reinter-
vention was 0.1 (0.10.6) years for residual VSD closure, 0.5
(0.10.6) years for combined residual VSD and PS surgery,
1.9 (1.07.3) years for PS surgery, 2.6 (1.68.5) years for per-
cutaneous treatment of PS, and 11.8 (5.914.1) years for PR
surgery (P < 0.001). Freedom from reintervention due to PSSeminars in Thoracic and Cardiovascular Surgery  Volume 00was similar in patients undergoing valve-sparing surgery and
patients undergoing correction with TAP (P = 0.314).
As displayed in the lower panel of Figure 3, mean freedom
from reoperation was 12.1 (95% CI 11.013.2) years. In total,
redo cardiac surgery was required in 43 patients (24%), of
whom 36 patients (84%) underwent 1 reoperation and a
minority of 7 patients (16%) underwent 2 reoperations during
follow-up.
Figure 4 displays freedom from reintervention based on age
at the moment of total ToF correction. ToF correction at age
<2 months had the shortest freedom from reintervention with
a mean interval of 6.8 (95% CI 4.98.9) years (P = 0.004 and
P = 0.043 compared to age 26 months and >6 months,
respectively). Correction at 26 months and >6 months of age, Number 00 5
Figure 3. Freedom from reintervention and reoperation.
Freedom from reintervention (upper) and freedom from reoper-
ation (lower). Conﬁdence intervals are displayed by interrupted
lines. Corresponding tables with the number of patients at risk
and the number of events for each time point are provided
below the plot.
CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERAshowed a similar freedom from reintervention with respective
intervals of 11.7 (95% CI 10.313.1) and 11.9 (95% CI
9.214.6) years (P = 0.923).
As shown in Table 3, univariate analysis identiﬁed use of
TAP, ToF correction at age <2 months, ToF-DORV/DCRV and
lower body weight at ToF correction as possible predictors for
future reintervention. Multivariate analyses identiﬁed ToF cor-
rection at age <2 months and DCRV/DORV as independent
predictors for reintervention.
Tachyarrhythmias and Cardiac Function Tests
Holter monitoring was performed, on clinical indication, in
41 patients and showed supraventricular or ventricular ectopy
in 27 patients, including supraventricular premature beats
(N = 23), SVcouplets (N = 2), SVruns (N = 2), VPB (N = 19),
Vcouplets (N = 6), and Vruns (N = 1). Only 8 patients had
>100 episodes of supraventricular ectopy and 2 patients had6 Seminars in Th>100 episodes of ventricular ectopy. None of the patients had
sustained episodes of regular SVT, AF, or VT. One patient
underwent ablative therapy for Wolf-Parkinson-White syn-
drome.
Nineteen patients underwent exercise testing at a mean age
of 11.9 § 2.1 (8.316.9) years, performing at a mean of 90
(60110)% of their predicted value; 5 patients showed ven-
tricular ectopy during exercise testing; no ST-T deviations
were observed during exercise testing.
Cardiac MRI was performed in 42 patients at a median inter-
val of 10.9 (8.413.0) years after total ToF correction.
Twenty-three (55%) of them did not have PS, whereas mild,
moderate, and severe PS was observed in, respectively, 12
(29%), 5 (12%), and 2 patients (5%). Median PR-fraction was
35 (2743)%.
Mean BSA-indexed LVEDV and RVEDV were 81 § 17
(24116) ml/m2 and 128 § 31 (57195) ml/m2, respectively.
Median LVEF and RVEF were, respectively, 56 (5261)% and
53(4858)%. Only 4 patients who underwent cardiac MRI
had undergone valve-sparing total ToF correction; therefore,
comparison of PR fraction, LVEF, and RVEF as assessed by
MRI was not possible.
Early and Late Mortality
A total of 5 patients (3%) died during follow-up, of whom
2 patients died within the ﬁrst postoperative month. Three
patients died of cardiovascular cause (age 5 months, 5 months,
and 9.3 years), 1 patient died of noncardiovascular cause
(age 14.4 years) and in 1 patient, cause of death could not be
identiﬁed. Both early and overall postoperative mortalities were
similar between patients without (N = 152) and with additional
syndromes (N = 25) (N = 1 [0.7%] vs N = 1 [4%], P = 0.263 and
N = 4 [2.6%] vs N = 1 [4%], P = 0.537, respectively).
However, prematurely/dysmaturely born patients showed an
increased risk of postoperative mortality. During 16-year
follow-up, mortality rate in a term newborns was 0.7%,
whereas mortality rate was 9.5% in prematurely/dysmaturely
born patients (N = 4, P < 0.003).
DISCUSSION
Key Findings
The present study reports on 15-year outcome of transatrial-
transpulmonary total ToF correction in the current era of surgi-
cal and perioperative management. Our data reveal an excel-
lent 15-year survival rate. Nevertheless, premature/dysmature
newborns had a higher mortality risk.
Tachyarrhythmias in the early postoperative phase were
observed in a minority of patients and none of the patients
required permanent pacemaker implantation due to early post-
operative conduction disorders.
During long-term follow-up, we observed a high rate of
residual PS and PR, requiring reintervention in a substantial
number of patients. Valve-sparing surgery resulted in a lower
incidence of PR during follow-up. Particularly the highoracic and Cardiovascular Surgery  Volume 00, Number 00
Figure 4. Freedom from reintervention according to age at total ToF correction.
Kaplan-Meier plot describing differences in freedom from reintervention according to age at the moment of total ToF correction.
Conﬁdence intervals are displayed by interrupted lines. Corresponding tables with the number of patients at risk and the number
of events for each time point are provided below the plot.
CONGENITAL  TETRALOGY OF FALLOT IN THE CURRENT ERAincidence of PR is worrisome, as it may lead to RV and RA dila-
tion and thereby deterioration of cardiac function and arrhyth-
mia development over time. Prospective follow-up by cardiac
MRI is recommended.Table 3. Predictors for Reintervention
OR 95% CI P Value
Univariate analysisD3X X
Transannular patch 1.75 0.8743.511 0.114
ToF correction <2 m 2.50 1.3404.654 0.004
Syndromic disease 1.06 0.4992.266 0.873
Premature/dysmature 1.03 0.5242.005 0.943
DORV/DCRV 2.16 0.1204.153 0.021
Weight 0.89 0.7541.042 0.145
Palliative shunt 0.97 0.2353.990 0.964
Multivariate analysis D4X X
Transannular patch 1.71 0.8293.539 0.146
ToF correction <2 m 2.06 1.0344.095 0.040
Syndromic disease   
Premature/dysmature   
DORV/DCRV 2.44 1.2514.775 0.009
Weight 0.921 0.7811.087 0.332
Palliative shunt   
Seminars in Thoracic and Cardiovascular Surgery  Volume 00Management of the Right Ventricular Outﬂow Tract
Particularly in ToF patients, improved surgical and periopera-
tive management lead to survival into adulthood. Yet, long-term
survival is often characterized by the necessity of (multiple)
reinterventions and development of tachyarrhythmias.
While in the early years of ToF correction PR was considered
a benign condition which was well tolerated, it is now recog-
nized that chronic PR leads to ventricular deterioration and
increased arrhythmogenesis over time.1113
To date, surgical approach of ToF correction is focused more
and more on preservation of the pulmonary valve. A broad
scala of valve-sparing surgical techniques exists, of which the
most commonly used include infundibulectomy, commisurot-
omy, supra-annular pulmonary artery patch placement, Hegar
dilation, and balloon dilation.11,14 However, preservation of
the native pulmonary valve is not always possible, and even if
possible, the beneﬁcial results of valve-sparing techniques are
not ever-lasting.
Residual Pulmonary Regurgitation
In our cohort, incidence of greater than or equal to moderate
PR in the ﬁrst year after surgery was similar to previous reports
by Sen et al15 and Vida et al,16 who observed greater than or
equal to moderate PR in, respectively, 20% and 14% of, Number 00 7
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9 months’ and 2.8 years’ follow-up.
However, even though valve-sparing surgery drastically
reduced the rate of PR development compared to TAP correc-
tion, freedom of D29X Xatleast moderate PR declined from 66% at 5-
year follow-up to 55% at 10-year follow-up after valve-sparing
surgery.
The progressive nature of residual PR even in patients with
valve-sparing surgery was also conﬁrmed in a study by Hickey
et al.17 In their population, D30X Xatleast moderate PR occurred in
14% of patients undergoing valve-sparing surgery early after
surgery, which progressed to 67% after 5.6 years’ follow-up.
Similarly, in a recent study by Hofferberth et al, patients
undergoing valve-sparing repair with intraoperative balloon
dilation developed progressive PR over time.18 Freedom of
D31X Xatleast moderate PR at 5-year follow-up was only 43%. It
appeared that valve leaﬂet growth was not commensurate with
annular growth. The authors hypothesized that although surgi-
cal intervention may lead to satisfactory short-term outcomes
by altering valvular morphology, valve deterioration over time
seems common even in patients with excellent early valvular
function. Their ﬁndings suggest that long-term biological
behavior is not altered by surgical intervention.Residual Pulmonary Stenosis
Overall, freedom from D32X Xatleast moderate PS was 50% and
46% after, respectively, 5- and 10-year follow-up after TAP
correction and 69% and 69% after, respectively,
5- and 10-year follow-up after valve-sparing correction.
Against our expectations, mean freedom from residual PS in
our cohort was thus longer in patients with valve-sparing cor-
rection, which may indicate that these patients also had less
initial RVOT obstruction and perhaps our criteria for valve-
sparing correction could be expanded to inclusion of smaller
annular sizes. Yet, keeping in mind that this is no guarantee of
long-term freedom from PR or reintervention and that there is
a substantial risk of intraoperative revision requiring additional
cardiopulmonary bypass pump runs to achieve surgical suc-
cess, as was reported in a recent study by Hickey et al.17
A compromise should be found between inclusion of
smaller annular sizes versus the risk of intraoperative revision
requiring additional pump runs.
However, it may also indicate that while pursuing an trans-
annular incision as limited as possible in those undergoing
TAP repair, muscle bundle resection in the RVOT is not sufﬁ-
cient enough even though intraoperative surgical success of
RVOT desobstruction was assessed by echocardiographic
Doppler ﬂow <2 m/s and at maximum half systemic pressures
in the RV. Subvalvular desobstruction of the RVOT may be
performed more aggressively in both valve-sparing and non-
valve-sparing surgery to prolong the freedom of residual PS
requiring reintervention.8 Seminars in ThReintervention Rates During Long-Term Follow-Up
This high amount of residual PS also reﬂected in our reinter-
vention rate, reaching 29% of the cohort during >10-year fol-
low-up, which is comparable to the ﬁndings of recent studies,
reporting reintervention rates between 10% and 20% during
up to 5-year follow-up.13,1517 Reintervention mainly was due
to residual RVOT stenosis; in correspondence to the reports of
Bacha et al and Sen et al,13,15 we observed no difference in
reintervention rates between TAP and valve-sparing proce-
dures.
An interesting ﬁnding, which was also recognized in previ-
ous reports, was the age dependency of the reintervention
rates. Our results clearly showed worse freedom from reinter-
vention when ToF correction was performed at age <2 months.
In addition to higher reintervention rates with younger age at
correction, previous studies also associated correction <3
months with increased postoperative morbidity including pro-
longed ventilation time, prolonged hospital stay, and pro-
longed lactate clearance.1921
It is likely that the higher reoperation rate is for a great part
due to the use of prosthetic materials with limited growth
potential in combination with a complex neonatal anatomy.
Moreover, as in our center age D33X X>2 months is preferred, correc-
tion at younger age is performed on indication usually due to
severe cyanotic spells in patients with usually more severe
obstruction and more complex anatomy, increasing the risk of
reintervention.
Limitations
Since this study included patients undergoing ToF correc-
tion between 2000 and 2015, patients are still of relatively
young age. As a result, none of the patients developed sus-
tained tachyarrhythmias yet and comparison on arrhythmo-
genesis between valve-sparing and nonvalve-sparing surgery
was therefore not possible. Furthermore, when interpreting
results on the development of postoperative PR and PS, one
must take into account that patients undergoing valve-sparing
and nonvalve-sparing surgery show a spectrum of different
morphologies and conclusions drawn should also be seen in
this perspective.
CONCLUSIONS
Although the 15-year outcome of the transatrial-transpul-
monary approach in terms of postoperative complications and
mortality rates is excellent, the high incidence of moderate and
severe PR is worrisome. Valve-sparing surgery is associated
with a lower incidence of PR, yet was surgically not possible in
the majority of patients. As arrhythmia development is largely
inﬂuenced by ventricular function, which is in turn subject
to the consequences of PR and use of transannular patches,
improved surgical techniques with limited myocardial scar-
ring can only reduce the arrhythmia burden to some
extent. To allow a bright future, management of ToF
patients should continuously focus on optimal preservation
of ventricular function.oracic and Cardiovascular Surgery  Volume 00, Number 00
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